Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > From the last CC

<< Previous

Bullboard Posts

Next >>

Comment by Trogarzonon Aug 04, 2023 9:29am

132 Views

Post# 35572969

RE:RE:RE:RE:From the last CC

The need convincing results in the 1b trial.. the proof is in the pudding. Whatever the market think about the company and management, in the end it is the pudding. I am witness to seing a market get it wrong with Th in the past. The most memorable instance was 2010 (All go review committee on Th1905). It's clearly a proof that the market is always wright theory can be wrong.

<< Previous

Bullboard Posts

Next >>

Corus reports Q1 profit drop in the face of falling revenue